Teri E Klein

List of Publications by Year
in descending order

54 papers	6,727 citations	159525 30 h-index	189801 50 g-index
57 all docs	57 docs citations	57 times ranked	9279 citing authors

#	Article	IF	Citations
1	<scp>PharmVar GeneFocus</scp>: <scp>SLCO1B1</scp>. Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	2.3	18
2	The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statinâ€Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics, 2022, 111, 1007-1021.	2.3	120
3	Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 759-768.	1.1	16
4	Scientific evidence and sourcesÂofÂknowledge for pharmacogenomics. , 2022, , 19-51.		0
5	ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2022, 24, 1407-1414.	1.1	119
6	PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	2.3	72
7	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	1.1	49
8	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1391-1398.	1.1	145
9	ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1381-1390.	1.1	356
10	An Evidenceâ€Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clinical Pharmacology and Therapeutics, 2021, 110, 563-572.	2.3	308
11	PharmVar GeneFocus: CYP2C9. Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	2.3	34
12	PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge. Current Protocols, 2021, 1, e226.	1.3	33
13	Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 2021, 54, 5-17.	1.7	96
14	An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics. , 2021, , .		1
15	The Clinical Pharmacogenetics Implementation Consortium: 10ÂYears Later. Clinical Pharmacology and Therapeutics, 2020, 107, 171-175.	2.3	207
16	Pharmacogenomics Clinical Annotation Tool (Pharm<scp>CAT</scp>). Clinical Pharmacology and Therapeutics, 2020, 107, 203-210.	2.3	65
17	Standardizing <scp>CYP</scp>2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science, 2020, 13, 116-124.	1.5	353
18	PharmVar GeneFocus: CYP2D6. Clinical Pharmacology and Therapeutics, 2020, 107, 154-170.	2.3	156

#	Article	IF	Citations
19	PharmGKB summary: very important pharmacogene information for CACNA1S. Pharmacogenetics and Genomics, 2020, 30, 34-44.	0.7	7
20	Effect of CYP3A4*22 and PPAR-Î± Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068.	1.0	2
21	Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for ‹i›CYP2C9‹/i› and Nonsteroidal Antiâ€Inflammatory Drugs. Clinical Pharmacology and Therapeutics, 2020, 108, 191-200.	2.3	195
22	Response to: Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacological Research, 2020, 158, 104838.	3.1	2
23	The ‹scp›ACCO‹/scp›u‹scp›NT‹/scp› Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. Clinical and Translational Science, 2019, 12, 209-217.	1.5	32
24	Clinical Pharmacogenetics Implementation Consortium Guideline for ‹scp›Cytochrome P450 (‹i›CYP‹/i›)‹/scp›‹i›2D6‹/i› Genotype and Atomoxetine Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 94-102.	2.3	152
25	The Evolution of PharmVar. Clinical Pharmacology and Therapeutics, 2019, 105, 29-32.	2.3	106
26	Essential Characteristics of Pharmacogenomics Study Publications. Clinical Pharmacology and Therapeutics, 2019, 105, 86-91.	2.3	9
27	Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research. Clinical Pharmacology and Therapeutics, 2019, 105, 1256-1262.	2.3	90
28	PGxMine: Text mining for curation of PharmGKB. , 2019, , .		7
29	Pharmacogenomics in dermatology: tools for understanding gene-drug associations. Seminars in Cutaneous Medicine and Surgery, 2019, 38, E19-E24.	1.6	3
30	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical Pharmacology and Therapeutics, 2018, 103, 778-786.	2.3	110
31	PharmGKB summary. Pharmacogenetics and Genomics, 2018, 28, 110-115.	0.7	12
32	Pharmacogenomics and big genomic data: from lab to clinic and back again. Human Molecular Genetics, 2018, 27, R72-R78.	1.4	28
33	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€"Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	1.2	24
34	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (‹i›CYP‹/i›) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	2.3	335
35	Substitutions for arginine at position 780 in triple helical domain of the Î±1(I) chain alter folding of the type I procollagen molecule and cause osteogenesis imperfecta. PLoS ONE, 2018, 13, e0200264.	1.1	16
36	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	0.6	53

#	Article	IF	Citations
37	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	1.1	365
38	Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges. Human Mutation, 2017, 38, 1182-1192.	1.1	39
39	PharmGKB summary. Pharmacogenetics and Genomics, 2017, 27, 201-209.	0.7	23
40	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2017, 19, 249-255.	1.1	1,398
41	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine, 2017, 19, 215-223.	1.1	410
42	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1977-1985.	0.5	79
43	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 796-801.	2.2	83
44	Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. PLoS Genetics, 2015, 11, e1005496.	1.5	23
45	Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic Proceedings, 2015, 90, 716-729.	1.4	44
46	Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics, 2015, 16, 1253-1263.	0.6	29
47	Evidence synthesis and guideline development in genomic medicine: current status and future prospects. Genetics in Medicine, 2015, 17, 63-67.	1.1	16
48	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current Drug Metabolism, 2014, 15, 209-217.	0.7	341
49	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	3.8	398
50	Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans. Blood, 2014, 124, 2298-2305.	0.6	57
51	PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS. , 2013, , .		9
52	An ?Omics? view of drug development. Drug Development Research, 2004, 62, 81-85.	1.4	8
53	Conformational preferences of substituted prolines in the collagen triple helix. , 2002, 64, 63.		1
54	Computed Free energy differences between point mutations in a collagen-like peptide. Biopolymers, 2001, 58, 347-353.	1.2	39